Natural Human Interferon β Plus Ribavirin Combination Therapy in Japanese Patients Infected with Hepatitis C Virus and a High Viral Load

被引:10
作者
Katamura, Yoshio [1 ]
Suzuki, Fumitaka [1 ]
Akuta, Norio [1 ]
Sezaki, Hitomi [1 ]
Yatsuji, Hiromi [1 ]
Nomura, Norihiro [1 ]
Kawamura, Yusuke [1 ]
Hosaka, Tetsuya [1 ]
Kobayashi, Masahiro [1 ]
Suzuki, Yoshiyuki [1 ]
Saito, Satoshi [1 ]
Arase, Yasuji [1 ]
Ikeda, Kenji [1 ]
Kobayashi, Mariko [2 ]
Kumada, Hiromitsu [1 ]
机构
[1] Toranomon Gen Hosp, Dept Hepatol, Tokyo, Japan
[2] Toranomon Gen Hosp, Res Inst Hepatol, Tokyo, Japan
关键词
hepatitis C virus; interferon beta; ribavirin; depression;
D O I
10.2169/internalmedicine.47.1436
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective The aim of this pilot study was to determine the safety and efficacy of natural human interferon beta (nIFN beta) plus ribavirin (RBV) in patients with chronic hepatitis C who did not respond to pegylated interferon alpha (PEG-IFN), with special emphasis on the incidence of mental disorders or refusal for fear of adverse effects. Methods We studied 19 patients with HCV genotype 1b, 2a or 2b and a high viral load, including 8 patients with mental disorders. They were treated with nIFN beta-RBV. Eleven patients with HCV genotype 1b of these patients were treated with nIFN beta-RBV for 48 weeks (group A), and compared with 22 matched controls treated with PEG-IFN plus RBV for 48 weeks (group B). The other 8 patients with HCV genotype 2 were treated with nIFN beta-RBV for 24 weeks. Results Six of 8 patients with mental disorders and 9 of 11 patients without mental disorders completed nIFN beta-RBV therapy; 1 patient with mental disorder dropped out due to exacerbation of depression, and 3 patients suspended the therapy due to insufficient response. The sustained virological response (SVR) was 27% (3/11) in group A and 41% (9/22) in group B (p = 0.70). During treatment, platelet count increased in group A but not in group B. SVR was 88% (7/8) in patients of genotype 2 and high viral load treated with nIFN beta plus RBV. Conclusion nIFN beta-RBV therapy offers sufficient safety and efficacy for patients with mental disorders, and thus could represent an excellent second-line therapy for subpopulations that are not suitable for PEG-IFN-RBV.
引用
收藏
页码:1827 / 1834
页数:8
相关论文
共 25 条
[1]   INTERFERON-BETA TREATMENT OF HUMAN-DISEASE [J].
ALAM, JJ .
CURRENT OPINION IN BIOTECHNOLOGY, 1995, 6 (06) :688-691
[2]  
Bernardinello E, 1999, HEPATO-GASTROENTEROL, V46, P3216
[3]   Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin [J].
Buti, M ;
Sanchez-Avila, F ;
Lurie, Y ;
Stalgis, C ;
Valdés, A ;
Martell, M ;
Esteban, R .
HEPATOLOGY, 2002, 35 (04) :930-936
[4]   Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C [J].
Chan, Henry L. Y. ;
Ren, Hong ;
Chow, Wan C. ;
Wee, Theodore .
HEPATOLOGY, 2007, 46 (02) :315-323
[5]   STRUCTURE OF THE HUMAN INTERFERON-ALPHA RECEPTOR [J].
COLAMONICI, OR ;
PFEFFER, LM .
PHARMACOLOGY & THERAPEUTICS, 1991, 52 (02) :227-233
[6]   Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays [J].
Der, SD ;
Zhou, AM ;
Williams, BRG ;
Silverman, RH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (26) :15623-15628
[7]   Interferon-β plus ribavirin for patients with hepatitis C virus genotype 1:: a randomised pilot trial [J].
Enomoto, M ;
Tamori, A ;
Kawada, N ;
Jomura, H ;
Nishiguchi, S ;
Saibara, T ;
Onishi, S ;
Mochida, S ;
Fujiwara, K .
GUT, 2006, 55 (01) :139-140
[8]  
Festi D, 2004, WORLD J GASTROENTERO, V10, P12
[9]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982
[10]   Side effects of therapy of hepatitis C and their management [J].
Fried, MW .
HEPATOLOGY, 2002, 36 (05) :S237-S244